234 related articles for article (PubMed ID: 28262623)
1. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model.
Waksman R; Zumstein P; Pritsch M; Wittchow E; Haude M; Lapointe-Corriveau C; Leclerc G; Joner M
EuroIntervention; 2017 Jul; 13(4):440-449. PubMed ID: 28262623
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study.
Toušek P; Lazarák T; Varvařovský I; Nováčková M; Neuberg M; Kočka V
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1129-1136. PubMed ID: 34505954
[TBL] [Abstract][Full Text] [Related]
3. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.
Farooq V; Serruys PW; Heo JH; Gogas BD; Onuma Y; Perkins LE; Diletti R; Radu MD; Räber L; Bourantas CV; Zhang Y; van Remortel E; Pawar R; Rapoza RJ; Powers JC; van Beusekom HM; Garcìa-Garcìa HM; Virmani R
JACC Cardiovasc Interv; 2013 May; 6(5):523-32. PubMed ID: 23702016
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of a Novel Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold in Porcine Coronary Artery at 6 Months.
Zheng JF; Qiu H; Tian Y; Hu XY; Luo T; Wu C; Tian Y; Tang Y; Song LF; Li L; Xu L; Xu B; Gao RL
JACC Cardiovasc Interv; 2019 Feb; 12(3):245-255. PubMed ID: 30732729
[TBL] [Abstract][Full Text] [Related]
5. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
[TBL] [Abstract][Full Text] [Related]
6. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.
Waksman R; Lipinski MJ; Acampado E; Cheng Q; Adams L; Torii S; Gai J; Torguson R; Hellinga DM; Westman PC; Joner M; Zumstein P; Kolodgie FD; Virmani R
Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28801538
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
[TBL] [Abstract][Full Text] [Related]
10. Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.
Buszman PP; Michalak MJ; Pruski M; Fernandez C; Jelonek M; Janas A; Savard C; Gwiazdowska-Nowotka B; Żurakowski A; Wojakowski W; Buszman PE; Milewski K
Cardiol J; 2016; 23(6):657-666. PubMed ID: 27976797
[TBL] [Abstract][Full Text] [Related]
11. Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt-chromium metallic stent?
Sotomi Y; Onuma Y; Miyazaki Y; Asano T; Katagiri Y; Tenekecioglu E; Jonker H; Dijkstra J; de Winter RJ; Wykrzykowska JJ; Stone GW; Popma JJ; Kozuma K; Tanabe K; Serruys PW; Kimura T
EuroIntervention; 2017 Aug; 13(5):e585-e594. PubMed ID: 28262625
[TBL] [Abstract][Full Text] [Related]
12. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
13. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
14. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model.
Otsuka F; Pacheco E; Perkins LE; Lane JP; Wang Q; Kamberi M; Frie M; Wang J; Sakakura K; Yahagi K; Ladich E; Rapoza RJ; Kolodgie FD; Virmani R
Circ Cardiovasc Interv; 2014 Jun; 7(3):330-42. PubMed ID: 24895447
[TBL] [Abstract][Full Text] [Related]
16. A head to head comparison of XINSORB bioresorbable sirolimus-eluting scaffold versus metallic sirolimus-eluting stent: 180 days follow-up in a porcine model.
Shen L; Wu Y; Ge L; Zhang Y; Wang Q; Qian J; Qiu Z; Ge J
Int J Cardiovasc Imaging; 2017 Oct; 33(10):1473-1481. PubMed ID: 28639098
[TBL] [Abstract][Full Text] [Related]
17. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
[TBL] [Abstract][Full Text] [Related]
18. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent.
Barkholt TØ; Webber B; Holm NR; Ormiston JA
Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149
[TBL] [Abstract][Full Text] [Related]
19. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
[TBL] [Abstract][Full Text] [Related]
20. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
